Medicenna Therapeutics Corp.

NASDAQ:MDNA

0.16 (USD) • At close November 14, 2024
Bedrijfsnaam Medicenna Therapeutics Corp.
Symbool MDNA
Munteenheid USD
Prijs 0.157
Beurswaarde 0
Dividendpercentage 0%
52-weken bereik 0.151 - 0.2
Industrie Biotechnology
Sector Healthcare
CEO Dr. Fahar Merchant Ph.D.
Website https://www.medicenna.com

An error occurred while fetching data.

Over Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well

Vergelijkbare Aandelen

Hepion Pharmaceuticals, Inc. logo

Hepion Pharmaceuticals, Inc.

HEPA

0.5 USD

Pro-Dex, Inc. logo

Pro-Dex, Inc.

PDEX

48.13 USD

MEI Pharma, Inc. logo

MEI Pharma, Inc.

MEIP

2.36 USD

Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc.

BDTX

2.19 USD

Molecular Templates, Inc. logo

Molecular Templates, Inc.

MTEM

0.107 USD

Solid Biosciences Inc. logo

Solid Biosciences Inc.

SLDB

4.18 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)